Acute Myeloid Leukemia Clinical Trial
Selecting a Favorable KIR Donor in Unrelated HCT for AML
Summary
Donors with favorable KIR B haplotype gene content have yielded reduced relapse risk and improved leukemia free survival (LFS) in retrospective analyses of unrelated donor (URD) hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML). Specifically, donors with more KIR B gene content and those who are homozygous for the centromeric (Cen) B haplotype genes (as opposed to the telomeric (Tel) genes confer the most protective effect. This study proposes to prospectively test and validate the utility and effectiveness of further informing URD identification and selection by KIR genotyping as a supplement to HLA matching and the other variables known or suspected to indicate the best URD for a patient.
Hypotheses:
Favorable KIR donors will improve protection against relapse and improve leukemia free survival (LFS) after URD HCT for AML.
Directed study procedures for rapid KIR genotyping and reporting to searching Transplant Centers (TC) can inform donor search and selection without delay in donor availability for HCT.
Full Description
Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor.
Eligibility Criteria
Inclusion Criteria:
Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT
Potential URD undergoing screening to provide a HCT graft to a patient with acute myeloid leukemia (AML) at a participating institution
Provides written consent
Exclusion Criteria:
Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor. In situations where the preferred (best > better > neutral) KIR donor is not selected in favor of a less favorable KIR genotype donor, the center will report one or more defined reasons (donor age; gender; parity; CMV status; ABO status; availability/logistics; other) for the choice (among equivalently HLA matched donors).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 19 Locations for this study
Scottsdale Arizona, 85259, United States
Denver Colorado, 80218, United States
Atlanta Georgia, 30322, United States
Chicago Illinois, 60637, United States
Indianapolis Indiana, 46202, United States
Kansas City Kansas, 66160, United States
Minneapolis Minnesota, 55455, United States
Rochester Minnesota, 55905, United States
Saint Louis Missouri, 63110, United States
Hackensack New Jersey, 07601, United States
Buffalo New York, 14263, United States
New York New York, 10021, United States
Cleveland Ohio, 44195, United States
Columbus Ohio, 43210, United States
Philadelphia Pennsylvania, 19104, United States
Dallas Texas, 75246, United States
Houston Texas, 77030, United States
San Antonio Texas, 78229, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.